Lenograstim is primarily eliminated by the kidney and
neutrophils/neutrophil precursors; the latter presumably
involves binding of the growth factor to the G-CSF
receptor on the cell surface, internalisation of the growth
factor-receptor complexes via endocytosis, and subsequent
degradation inside the cells. During chemotherapy induced neutropenia, the clearance of lenograstim is
significantly reduced and the concentration of lenograstim
is sustained until onset of neutrophil recovery.
